Nasdaq · Healthcare
Invivyd, Inc. (IVVD)
As-reported financials and recent SEC filings for Invivyd, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$53.4M
Net income
$-52.5M
Net margin
-98.2%
Diluted EPS
$-0.30
ROE
-21.7%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $53.4M | $25.4M | $0 | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | $-55.6M | $-176.9M | $-212.8M | $-248.0M | $-226.9M |
| Net income | $-52.5M | $-169.9M | $-198.6M | $-241.3M | $-226.8M |
| Diluted EPS | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-1.77 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-07-06
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →42026-05-21
View on EDGAR →8-K2026-05-19
View on EDGAR →Largest Healthcare peers
Go deeper on IVVD
Search Invivyd, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.